Akcea Therapeutics, PTC Therapeutics Partner to Commercialize Two Rare Disease Drugs in Latin America; PTC To Gain Exclusive Rights To TEGSEDI and WAYLIVRA In These Areas And Akcea To Receive Licensing Fee Of $18M